NantKwest Profile



Odds of Distress

Check how we calculate scores
Equity ratings for NantKwest are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting July 20, 2019 and ending today October 18, 2019. Click here to learn more.

NantKwest Profile

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. NantKwest operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 151 people. more
NantKwest Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NantKwest SEC Filings
NantKwest SEC Filings
Security & Exchange Commission EDGAR ReportsView All
President CEO, Board MemberBarry SimonView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCalifornia U.S.A
Business Address3530 John Hopkins Court, San Diego, CA 92121, United States
ExchangeBATS Exchange
CIK Number0001326110
Phone858 633 0300
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestSeptember 30, 2019
NantKwest (NK) is traded on BATS Exchange in USA. It is located in 3530 John Hopkins Court, San Diego, CA 92121, United States and employs 151 people. NantKwest is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with market capitalization of 114.04 M. NantKwest is active under Healthcare sector as part of Biotechnology industry. The entity has 98.31 M outstanding shares of which 3.01 M shares are now sold short in the market by investors with about 24.76 days to cover all shorted shares. NK reports about 84.05 M in cash with (61.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86.
Check NantKwest Probability Of Bankruptcy

Ownership Allocation (%)

NantKwest Target Price Odds Analysis

Odds Below 1.16HorizonTargetOdds Above 1.16
7.01%30 days 1.16 92.92%
Based on normal probability distribution, the odds of NantKwest to move above current price in 30 days from now is about 92.92 (This NantKwest probability density function shows the probability of NantKwest Stock to fall within a particular range of prices over 30 days) .

NantKwest Top Holders

NantKwest Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Simplex Trading LlcCall Options10913 K
Meeder Asset Management IncCommon Shares4.6 KK
Renaissance Technologies LlcCommon Shares1.5 M1.5 M
View NantKwest Diagnostics

NantKwest Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

NantKwest Key Fundamentals

NantKwest Against Markets

Did you try this?

Run Fund Screener Now


Fund Screener

Find activelly-traded funds from around the world traded on over 30 global exchanges
All  Next Launch Module

NantKwest Corporate Filings

NantKwest Corporate Filings

Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
Unclassified Corporate Event
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

NantKwest Corporate Directors

Cheryl Cohen Director
Richard Kusserow Independent Director
Michael Blaszyk Independent Director
Please see also Stocks Correlation. Please also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.